ArticleCurrent medicinal chemistry2003
Ribozyme-based gene-inactivation systems require a fine comprehension of their substrate specificities; the case of delta ribozyme.
Article in Current medicinal chemistry, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Design and testing of Hepatitis Delta Ribozymes for suppression of Chikungunya virus infection in cell cultures.Medical research archives · 2024Article
- Measuring specificity in multi-substrate/product systems as a tool to investigate selectivity in vivo.Biochimica et biophysica acta · 2016Review
- Silencing of amyloid precursor protein expression using a new engineered delta ribozyme.International journal of Alzheimer's disease · 2012Article
- Article
- Monitoring of an RNA multistep folding pathway by isothermal titration calorimetry.Biophysical journal · 2009Article
- Hairpin ribozyme-antisense RNA constructs can act as molecular Lassos.Nucleic acids research · 2008Article
- Development of an isoform-specific gene suppression system: the study of the human Pax-5B transcriptional element.Nucleic acids research · 2008Article
- A novel structural rearrangement of hepatitis delta virus antigenomic ribozyme.Nucleic acids research · 2007Article
- Examination of the folding pathway of the antigenomic hepatitis delta virus ribozyme reveals key interactions of the L3 loop.RNA (New York, N.Y.) · 2007Article
- RiboSubstrates: a web application addressing the cleavage specificities of ribozymes in designated genomes.BMC bioinformatics · 2006Article
- Unbiased in vitro selection reveals the unique character of the self-cleaving antigenomic HDV RNA sequence.Nucleic acids research · 2006Article
- Gene targeting in the Gram-Positive bacterium Lactococcus lactis, using various delta ribozymes.Applied and environmental microbiology · 2006Article
- Functional characterization of the SOFA delta ribozyme.RNA (New York, N.Y.) · 2005Article
- Target-dependent on/off switch increases ribozyme fidelity.Nucleic acids research · 2005Article
- Cross-linking experiments reveal the presence of novel structural features between a hepatitis delta virus ribozyme and its substrate.RNA (New York, N.Y.) · 2004Article
- Silencing of SPC2 expression using an engineered delta ribozyme in the mouse betaTC-3 endocrine cell line.The Journal of biological chemistry · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The ability of ribozymes (i.e. RNA enzymes) to specifically recognize and subsequently catalyze the cleavage of an RNA substrate makes them attractive for the development of therapeutic tools for the inactivation of both viral RNAs and mRNAs associated with various diseases. Several applicable ribozyme models have been tested both in vitro and in a cellular environment, and have shown significant promise. However, several hurdles remain to be surpassed before we generate a useful gene-inactivation system based on a ribozyme. Among the most important requirements for further progress are a better understanding of the features that contribute to defining the substrate specificity for cleavage by a ribozyme, and the identification of the potential cleavage sites in a given target RNA. The goal of this review is to illustrate the importance of both of these factors at the RNA level in the development of any type of ribozyme based gene-therapy. This is achieved by reviewing the recent progress in both the structure-function relationships and the development of a gene-inactivation system of a model ribozyme, specifically delta ribozyme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.